Developer docs
API playgroundTry for free, no card

Search company profiles

InMed Pharmaceuticals

Full company profile

uuid0000fgz

Namestring
InMed Pharmaceuticals
Legal namestring
InMed Pharmaceuticals Inc.
Websiteurl
inmedpharma.com
Company typeenum
Public
Founded yearint
1981
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabinoid pharmaceutical development, Alzheimer's drug research, clinical-stage biotechnology, rare cannabinoid manufacturing, migraine therapy development
Industry3 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAIAE
Headache & Migraine Medicine
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Drug Development
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Development
TypeLicensing Royalties
Description

Revenue generation through development of drug candidates targeting Alzheimer's disease (INM-901), dry AMD (INM-089), and migraine prevention (via Mentari Therapeutics merger MT-001, MT-002). Currently pre-revenue as all programs are in preclinical/clinical stage.

biospace.com
2BayMedica Commercial Cannabinoid Sales
TypeOne Time License
Description

Commercial sales of rare, non-intoxicating cannabinoids through BayMedica subsidiary to the health and wellness sector. Revenue declining 26% YoY to $0.8M in Q2 FY2026. Operations being wound down by June 30, 2026 due to U.S. legislation H.R. 5371.

newsfilecorp.com
3Capital Markets / Private Placements
TypeTransaction Fee
Description

Revenue through capital raises including private placements, registered direct offerings, and at-the-market share offerings to fund pipeline development and operations. Major transactions include $6M (Sept 2022), $5M (June 2022), $12M (July 2021), and $290M private placement for Mentari merger (May 2026).

globenewswire.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary cannabinoid-based and biologic drug candidates targeting high unmet medical needs. Core pipeline assets include INM-901 for Alzheimer's disease (targeting neuroinflammation via endocannabinoid CB1/CB2 receptors) and INM-089 for dry age-related macular degeneration, with the SVN-SDN-14 series (antidepressant activity) as additional pipeline candidates. Post-merger with Mentari Therapeutics (May 2026), the company will add migraine prevention candidates MT-001 (anti-PACAP antibody) and MT-002 (anti-CGRP x PACAP bispecific). The BayMedica subsidiary historically supplied rare non-intoxicating cannabinoids to the health and wellness sector but is being wound down by June 30, 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • INM-901 demonstrated dose-dependent reduction of IL-6 and IL-8 pro-inflammatory markers in 3D human brain organoid models
+3 more records
Product overview1 text field

InMed Pharmaceuticals is a pharmaceutical company focused on drug development for high unmet medical needs. The company's core pipeline includes INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration. Through its subsidiary BayMedica (acquired September 2021), it previously manufactured rare cannabinoids for health and wellness, though this commercial segment is being wound down by June 2026. The company has announced a merger with Mentari Therapeutics to add migraine prevention candidates MT-001 and MT-002 to its portfolio. InMed historically developed small molecule drug candidates targeting CB1/CB2 receptors.

Product and service6 records
1INM-901
CategoryDrug Candidate (CNS / Neurology)
Description

INM-901 is a proprietary drug candidate for Alzheimer's disease targeting neuroinflammation via the endocannabinoid system (CB1/CB2 receptors). Preclinical data in 3D human brain organoid models and animal studies demonstrate dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8, with neuroprotection, neuritogenesis, and behavioral improvements. Pharmacokinetic studies showed robust bioavailability with no adverse neurological effects in large animal models.

2INM-089
CategoryDrug Candidate (Ophthalmology)
Description

INM-089 is a drug candidate for the treatment of dry age-related macular degeneration (dry AMD), addressing an unmet medical need where no approved disease-modifying therapies currently exist. The candidate is advancing toward a pre-IND meeting with the FDA in Q4 2026.

3SVN-SDN-14 Series Compounds
CategoryDrug Candidate (CNS / Depression)
Description

The SVN-SDN-14 series consists of patent-pending small molecule drug candidates targeting the endocannabinoid system with demonstrated antidepressant-like activity benchmarked against fluoxetine (Prozac), supporting potential therapeutic applications for patients with inadequate SSRI response.

4MT-001 (post-Mentari merger)
CategoryDrug Candidate (Migraine / Neurology)
Description

MT-001 is an anti-PACAP antibody targeting migraine prevention through a mechanism distinct from the CGRP pathway, addressing unmet need in patients who respond suboptimally to existing approved therapies. Regulatory filing is planned for mid-2026.

5MT-002 (post-Mentari merger)
CategoryDrug Candidate (Migraine / Neurology)
Description

MT-002 is an anti-CGRP x PACAP bispecific antibody for migraine prevention, designed to address patients who respond suboptimally to current approved therapies by targeting both pathways simultaneously. Regulatory filing is planned for Q1 2027.

6BayMedica Rare Cannabinoids
CategoryCommercial Cannabinoid Manufacturing
Description

BayMedica is a wholly owned subsidiary of InMed Pharmaceuticals that manufactured and sold rare, non-intoxicating cannabinoids for the health and wellness sector using proprietary processes. Commercial operations are being wound down by June 30, 2026 due to anticipated negative impacts from U.S. federal legislation H.R. 5371; revenue was $0.8M in Q2 FY2026, declining 26% YoY.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

InMed entered into a definitive all-stock merger agreement with Mentari Therapeutics in May 2026. The merger combines Mentari's migraine prevention drug pipeline (MT-001 anti-PACAP antibody, MT-002 anti-CGRP x PACAP bispecific) with InMed's public market infrastructure. The combined entity operates as Mentari Therapeutics on Nasdaq with approximately $421.4 million pro forma equity value.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-01
Description

InMed collaborated with Stem Pharm, Inc. for preclinical validation studies using 3D human brain organoid models to demonstrate INM-901's reduction of neuroinflammation in Alzheimer's disease models. The studies showed dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8, aligning with prior animal model findings.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-01
Description

InMed Pharmaceuticals acquired BayMedica, a US-based company specializing in manufacturing rare cannabinoids, in September 2021. The acquisition aimed to position InMed as a global leader in cannabinoid manufacturing and expand its product pipeline with high-value cannabinoid products. BayMedica's commercial operations are being wound down by June 30, 2026 due to anticipated negative impacts from U.S. legislation H.R. 5371.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage-to-commercial CNS specialty pharma with FDA-approved migraine therapy Qulipta (CGRP antagonist) and Auvelity for depression — directly comparable to InMed/Mentari's CNS pipeline focus and indication overlap.

TypeDirect peer
Description

Clinical-stage CNS company developing migraine therapies and other neurological candidates, with comparable small-cap profile and pipeline-stage risk/reward similar to InMed/Mentari.

TypeDirect peer
Description

Migraine-focused specialty pharma (Nurtec ODT) and CNS pipeline developer — directly comparable therapeutic focus and development stage for the post-merger Mentari migraine assets.

TypeDirect peer
Description

CNS specialty pharma with depression and neurology pipeline (Zurzuvae) — comparable clinical-stage CNS drug developer with similar indication overlap to InMed's neurology programs.

TypeDirect peer
Description

Cannabinoid-based pharmaceutical developer focused on CNS disorders, with a CB1-targeting platform — directly comparable mechanism and therapeutic focus to InMed's cannabinoid approach.

TypeBroad incumbent
Description

Specialty pharma with Epidiolex (cannabidiol) and a CNS franchise including migraine therapy — established player with overlapping cannabinoid-pharma and migraine therapeutics comparable to InMed/Mentari's pipeline.

TypeBroad incumbent
Description

Specialty pharma with strong neurology/migraine franchise (Vyepti anti-CGRP) — direct therapeutic-area incumbent comparable to the migraine focus of post-merger pipeline.

TypeBroad incumbent
Description

Large pharma with migraine franchise (Ubrelvy CGRP antagonist) and neurology pipeline — comparable therapeutic area and potential strategic acquirer of CNS assets like InMed/Mentari's pipeline.

TypeBroad incumbent
Description

Large pharma with migraine asset (Nurtec ODT) via Biohaven acquisition and active CNS investing — comparable migraine therapeutic exposure and potential partnership/acquisition counterparty.

TypeEmerging player
Description

Specialty CNS pharma focused on cortisol-modulating therapies with comparable small/mid-cap profile — comparable scale and commercial-stage CNS drug development model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InMed Pharmaceuticals

Biopharmaceutical Drug Developmentinmedpharma.com

InMed Pharmaceuticals firmographics

Firmographics
Name
InMed Pharmaceuticals
Legal name
InMed Pharmaceuticals Inc.
Website
https://inmedpharma.com
Company type
Public
Founded year
1981
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

InMed Pharmaceuticals industry classification

Industry
Product category
Biopharmaceutical Drug Development
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAKAIAE
Headache & Migraine Medicine

Keywords

  • Cannabinoid pharmaceutical development
  • Alzheimer's drug research
  • Clinical-stage biotechnology
  • Rare cannabinoid manufacturing
  • Migraine therapy development

Where InMed Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

InMed Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development: Revenue generation through development of drug candidates targeting Alzheimer's disease (INM-901), dry AMD (INM-089), and migraine prevention (via Mentari Therapeutics merger MT-001, MT-002). Currently pre-revenue as all programs are in preclinical/clinical stage.
  2. BayMedica Commercial Cannabinoid Sales: Commercial sales of rare, non-intoxicating cannabinoids through BayMedica subsidiary to the health and wellness sector. Revenue declining 26% YoY to $0.8M in Q2 FY2026. Operations being wound down by June 30, 2026 due to U.S. legislation H.R. 5371.
  3. Capital Markets / Private Placements: Revenue through capital raises including private placements, registered direct offerings, and at-the-market share offerings to fund pipeline development and operations. Major transactions include $6M (Sept 2022), $5M (June 2022), $12M (July 2021), and $290M private placement for Mentari merger (May 2026).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

InMed Pharmaceuticals product offering

Product offering

Core offering

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary cannabinoid-based and biologic drug candidates targeting high unmet medical needs. Core pipeline assets include INM-901 for Alzheimer's disease (targeting neuroinflammation via endocannabinoid CB1/CB2 receptors) and INM-089 for dry age-related macular degeneration, with the SVN-SDN-14 series (antidepressant activity) as additional pipeline candidates. Post-merger with Mentari Therapeutics (May 2026), the company will add migraine prevention candidates MT-001 (anti-PACAP antibody) and MT-002 (anti-CGRP x PACAP bispecific). The BayMedica subsidiary historically supplied rare non-intoxicating cannabinoids to the health and wellness sector but is being wound down by June 30, 2026.

Product overview

InMed Pharmaceuticals is a pharmaceutical company focused on drug development for high unmet medical needs. The company's core pipeline includes INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration. Through its subsidiary BayMedica (acquired September 2021), it previously manufactured rare cannabinoids for health and wellness, though this commercial segment is being wound down by June 2026. The company has announced a merger with Mentari Therapeutics to add migraine prevention candidates MT-001 and MT-002 to its portfolio. InMed historically developed small molecule drug candidates targeting CB1/CB2 receptors.

Differentiator

Problem solved

Functional benefit

Products and services

  • INM-901 INM-901 is a proprietary drug candidate for Alzheimer's disease targeting neuroinflammation via the endocannabinoid system (CB1/CB2 receptors). Preclinical data in 3D human brain organoid models and animal studies demonstrate dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8, with neuroprotection, neuritogenesis, and behavioral improvements. Pharmacokinetic studies showed robust bioavailability with no adverse neurological effects in large animal models.
  • INM-089 INM-089 is a drug candidate for the treatment of dry age-related macular degeneration (dry AMD), addressing an unmet medical need where no approved disease-modifying therapies currently exist. The candidate is advancing toward a pre-IND meeting with the FDA in Q4 2026.
  • SVN-SDN-14 Series Compounds The SVN-SDN-14 series consists of patent-pending small molecule drug candidates targeting the endocannabinoid system with demonstrated antidepressant-like activity benchmarked against fluoxetine (Prozac), supporting potential therapeutic applications for patients with inadequate SSRI response.
  • MT-001 (post-Mentari merger) MT-001 is an anti-PACAP antibody targeting migraine prevention through a mechanism distinct from the CGRP pathway, addressing unmet need in patients who respond suboptimally to existing approved therapies. Regulatory filing is planned for mid-2026.
  • MT-002 (post-Mentari merger) MT-002 is an anti-CGRP x PACAP bispecific antibody for migraine prevention, designed to address patients who respond suboptimally to current approved therapies by targeting both pathways simultaneously. Regulatory filing is planned for Q1 2027.
  • BayMedica Rare Cannabinoids BayMedica is a wholly owned subsidiary of InMed Pharmaceuticals that manufactured and sold rare, non-intoxicating cannabinoids for the health and wellness sector using proprietary processes. Commercial operations are being wound down by June 30, 2026 due to anticipated negative impacts from U.S. federal legislation H.R. 5371; revenue was $0.8M in Q2 FY2026, declining 26% YoY.

Quantifiable outcome

  • INM-901 demonstrated dose-dependent reduction of IL-6 and IL-8 pro-inflammatory markers in 3D human brain organoid models
  • +3 more outcomes

Companies that use InMed Pharmaceuticals

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

InMed Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

InMed Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Mentari TherapeuticscoreStrategic or Co-development Partner · 1 May 2026InMed entered into a definitive all-stock merger agreement with Mentari Therapeutics in May 2026. The merger combines Mentari's migraine prevention drug pipeline (MT-001 anti-PACAP antibody, MT-002 anti-CGRP x PACAP bispecific) with InMed's public market infrastructure. The combined entity operates as Mentari Therapeutics on Nasdaq with approximately $421.4 million pro forma equity value.
  • Stem Pharm, Inc.coreTechnology or Integration · 1 March 2026InMed collaborated with Stem Pharm, Inc. for preclinical validation studies using 3D human brain organoid models to demonstrate INM-901's reduction of neuroinflammation in Alzheimer's disease models. The studies showed dose-dependent reduction of pro-inflammatory markers IL-6 and IL-8, aligning with prior animal model findings.
  • BayMedicacoreStrategic or Co-development Partner · 1 September 2021InMed Pharmaceuticals acquired BayMedica, a US-based company specializing in manufacturing rare cannabinoids, in September 2021. The acquisition aimed to position InMed as a global leader in cannabinoid manufacturing and expand its product pipeline with high-value cannabinoid products. BayMedica's commercial operations are being wound down by June 30, 2026 due to anticipated negative impacts from U.S. legislation H.R. 5371.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

InMed Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Axsome Therapeutics: Clinical-stage-to-commercial CNS specialty pharma with FDA-approved migraine therapy Qulipta (CGRP antagonist) and Auvelity for depression — directly comparable to InMed/Mentari's CNS pipeline focus and indication overlap.
  • Tonix Pharmaceuticals: Clinical-stage CNS company developing migraine therapies and other neurological candidates, with comparable small-cap profile and pipeline-stage risk/reward similar to InMed/Mentari.
  • Biohaven Pharmaceuticals: Migraine-focused specialty pharma (Nurtec ODT) and CNS pipeline developer — directly comparable therapeutic focus and development stage for the post-merger Mentari migraine assets.
  • Sage Therapeutics: CNS specialty pharma with depression and neurology pipeline (Zurzuvae) — comparable clinical-stage CNS drug developer with similar indication overlap to InMed's neurology programs.
  • Aelis Farma: Cannabinoid-based pharmaceutical developer focused on CNS disorders, with a CB1-targeting platform — directly comparable mechanism and therapeutic focus to InMed's cannabinoid approach.

Broad incumbents

  • Jazz Pharmaceuticals: Specialty pharma with Epidiolex (cannabidiol) and a CNS franchise including migraine therapy — established player with overlapping cannabinoid-pharma and migraine therapeutics comparable to InMed/Mentari's pipeline.
  • Lundbeck: Specialty pharma with strong neurology/migraine franchise (Vyepti anti-CGRP) — direct therapeutic-area incumbent comparable to the migraine focus of post-merger pipeline.
  • AbbVie: Large pharma with migraine franchise (Ubrelvy CGRP antagonist) and neurology pipeline — comparable therapeutic area and potential strategic acquirer of CNS assets like InMed/Mentari's pipeline.
  • Pfizer: Large pharma with migraine asset (Nurtec ODT) via Biohaven acquisition and active CNS investing — comparable migraine therapeutic exposure and potential partnership/acquisition counterparty.

Emerging players

  • Corcept Therapeutics: Specialty CNS pharma focused on cortisol-modulating therapies with comparable small/mid-cap profile — comparable scale and commercial-stage CNS drug development model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

InMed Pharmaceuticals social profiles

Digital presence

InMed Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InMed Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles6 records

InMed Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

InMed Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InMed Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InMed Pharmaceuticals

What does InMed Pharmaceuticals do?

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company developing proprietary cannabinoid-based and biologic drug candidates targeting high unmet medical needs. Core pipeline assets include INM-901 for Alzheimer's disease (targeting neuroinflammation via endocannabinoid CB1/CB2 receptors) and INM-089 for dry age-related macular degeneration, with the SVN-SDN-14 series (antidepressant activity) as additional pipeline candidates. Post-merger with Mentari Therapeutics (May 2026), the company will add migraine prevention candidates MT-001 (anti-PACAP antibody) and MT-002 (anti-CGRP x PACAP bispecific). The BayMedica subsidiary historically supplied rare non-intoxicating cannabinoids to the health and wellness sector but is being wound down by June 30, 2026.

Is InMed Pharmaceuticals a public or private company?

InMed Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was InMed Pharmaceuticals founded?

InMed Pharmaceuticals was founded in 1981. It employs 11 to 50 people.

Where is InMed Pharmaceuticals based?

InMed Pharmaceuticals is headquartered in Vancouver, Canada, in the North America region.

How does InMed Pharmaceuticals make money?

Three revenue lines are on record. Pharmaceutical Development is the primary driver. The others are bayMedica Commercial Cannabinoid Sales and capital Markets / Private Placements.

Who are InMed Pharmaceuticals's main competitors?

Direct peers on record are Axsome Therapeutics, Tonix Pharmaceuticals, Biohaven Pharmaceuticals, Sage Therapeutics and Aelis Farma. Broad incumbents are Jazz Pharmaceuticals, Lundbeck, AbbVie and Pfizer. Corcept Therapeutics is listed as an emerging player.

Does InMed Pharmaceuticals have an API?

No public API is recorded for InMed Pharmaceuticals.

What industry is InMed Pharmaceuticals in?

InMed Pharmaceuticals's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeInMed Pro Forma Net Loss Reaches $37.3 Million in First Half 2026 | INM Stock NewsInMed, renamed Mentari Therapeutics, reported a pro forma combined net loss of $37.3 million for the six months ended June 30, 2026, with a loss per share of $0.64. The merger closed on November 6, 2026, after a $490 million pre-closing financing, and the company remains focused on migraine prevention therapies.Business & FinancialMentari Therapeutics Announces Closing Of Merger With Inmed Pharmaceuticals And Previously Announced $490 Million FinancingMentari Therapeutics closed its merger with InMed Pharmaceuticals, with shares trading on Nasdaq under 'MTRI' on November 9, 2026. The company completed $490 million in private financings, providing runway into 2029. Its lead programs MT-001 and MT-002 are expected to share initial data in 2027.YahooMentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million FinancingMentari Therapeutics completed its merger with InMed Pharmaceuticals, with shares trading on Nasdaq under 'MTRI' starting November 9, 2026. The company raised $490 million in private financings, providing runway into 2029. Its lead programs MT-001 and MT-002 target migraine pathways, with initial data expected in 2027.Business & FinancialFox-Roku's $22B Deal, A New Nasdaq Biotech And A $25B Chemicals Tie-Up: Deals Investors Are WatchingFox completed its $22 billion acquisition of Roku on Friday, while InMed Pharmaceuticals merged with Mentari Therapeutics and will trade as MTRI on Nasdaq. AkzoNobel and Axalta received EU approval for a $25 billion merger conditional on selling European assets.Pulse 2.0Mentari Therapeutics Completes InMed Pharmaceuticals Merger Following Approximately $490 Million In FinancingMentari Therapeutics completed its merger with InMed Pharmaceuticals after raising about $490 million in private financing. The combined company will trade on Nasdaq under MTRI on November 9, 2026, and will pursue its migraine prevention programs MT-001 and MT-002.Dealroom.coCannabis firm InMed becomes migraine biotech Mentari in merger backed by $490MInMed Pharmaceuticals merged with Mentari Therapeutics, converting InMed into a vehicle for Mentari's migraine-prevention pipeline. The combined company, trading as MTRI, is backed by roughly $490 million in private financings, including $50 million in convertible notes. Mentari's lead programs target migraine, with development funding through 2029.PR NewswireInMed Pharmaceuticals Completes Closing of Merger with Mentari TherapeuticsInMed Pharmaceuticals completed its merger with Mentari Therapeutics, with shares trading on Nasdaq under 'MTRI' starting November 9, 2026. Pre-merger Mentari raised about $490 million in gross proceeds, including $50 million in convertible notes. The combined company will operate as Mentari Therapeutics, developing migraine therapies.PR NewswireInMed Pharmaceuticals Completes Closing of Merger with Mentari TherapeuticsInMed Pharmaceuticals completed its merger with Mentari Therapeutics, with shares trading on Nasdaq under 'MTRI' starting November 9, 2026. The combined company redomesticated to Nevada and raised about $490 million in gross proceeds, including $50 million in convertible notes. Mentari's lead programs target migraine prevention.Stock TitanInMed Completes Mentari Merger After About $490M FinancingInMed Pharmaceuticals completed its merger with Mentari Therapeutics, with shares expected to trade on Nasdaq under the ticker MTRI starting November 9, 2026. The combined company received approximately $490 million in gross proceeds, including conversion of $50 million in convertible notes. The company will operate as Mentari Therapeutics, developing migraine therapies MT-001 and MT-002.American Banking and Market NewsHead-To-Head Contrast: InMed Pharmaceuticals (NASDAQ:INM) versus BioAge Labs (NASDAQ:BIOA)BioAge Labs beats InMed Pharmaceuticals on 9 of 14 factors, including analyst ratings and valuation. BioAge Labs has a consensus price target of $33.00, implying 454.62% upside, while InMed's beta is lower at 0.94. BioAge Labs plans Phase 2 trials for its lead candidate azelaprag in 2025.